Narrator: This is Science Today. Researchers at the University of California, San Francisco are close to developing a promising vaccine for ductal carcinoma in-situ, an early form of breast cancer which is not yet invasive. Oncologist John Park says the vaccine, which would target a protein present in this type of cancer, should be tested on patients within the next few years.
Park: Patients have been looking forward to therapies like this for some time because they make a lot of sense. And fortunately, scientifically they're making more sense now then previously. So now that we know more about how cancers operate, we know what makes them different from normal cells, we can try to exploit that.
Narrator: Park says up to 40 percent of all the breast cancers detected are ductal carcinoma in-situ.
Park: It is a mixed blessing..it's fortunate that it's caught early but at the same time if the treatment is no better than if it were caught not as early, then it doesn't benefit that particular woman that much. So we'd like it truly to be a benefit to catch these cancers early and then actually do something about them in a way that's minimally invasive and as trouble free as possible.
Narrator: For Science Today, I'm Larissa Branin.